Clinical Trials Browser

Phase 1 × Completed × zimberelimab × Clear all

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Stomach Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT03628677 2025-02-04

A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies

Phase 1 Completed

75 enrolled

Other solid neoplasm

Solid Tumor, Unspecified, Adult

NCT03846310 2024-12-09

ARC-4

Phase 1 Completed

77 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04087018 2024-09-19

Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors

Phase 1 Completed

18 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT03629756 2024-05-24

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Phase 1 Completed

48 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms

NCT03713905 2023-04-10

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

Phase 1 Completed

293 enrolled

Other solid neoplasm

Advanced Solid Tumors

Clinical Trials

ARC-12

A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies

ARC-4

Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors